ABSTRACT
Human metapneumovirus (hMPV) is an emerging human pulmonary pathogen that is genetically related to respiratory syncytial virus. It has been increasingly associated with respiratory illnesses over the last few decades. Immunocompromised patients are particularly susceptible with resultant morbidity and mortality. We describe our experience with 9 immunocompromised patients diagnosed with pneumonia secondary to hMPV, 2 of whom were successfully treated with aerosolized and oral ribavirin along with intravenous immunoglobulin (IVIG). We suggest that hMPV should be considered in the differential diagnosis of immunocompromised patients with acute respiratory illness. Ribavirin (oral and aerosolized) with IVIG is potentially an effective treatment option for those with severe disease.
Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Lung Transplantation/adverse effects , Metapneumovirus , Paramyxoviridae Infections , Respiratory Tract Infections , Adult , Aged , Antiviral Agents/therapeutic use , Female , Humans , Immunocompromised Host , Immunoglobulins, Intravenous/therapeutic use , Male , Middle Aged , Paramyxoviridae Infections/drug therapy , Paramyxoviridae Infections/physiopathology , Paramyxoviridae Infections/virology , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/physiopathology , Respiratory Tract Infections/virology , Ribavirin/therapeutic use , Treatment OutcomeABSTRACT
Trimethoprim-Rhabdomyolysis is a serious, potentially life-threatening complication diagnosed when creatine phosphokinase levels exceed 1000 U/L. Although many drugs are associated with rhabdomyolysis, the previous reports of trimethoprim-sulfamethoxazole (TMP/SMX)-induced rhabdomyolysis have involved patients with human immunodeficiency virus/acquired immunodeficiency syndrome. This is the first report, to our knowledge, of TMP/SMX-induced rhabdomyolysis in an allogeneic stem cell transplant patient.
